US Patent

US11649259 — Polymorphic forms of deoxycytidine, compositions comprising the same and uses

Method of Use · Assigned to Zogenix MDS Inc · Expires 2040-08-19 · 14y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects polymorphic forms of deoxycytidine and methods for using compositions comprising these forms to treat mitochondrial diseases.

USPTO Abstract

Polymorphic forms of deoxycytidine and methods for preparing the same are provided herein. Also provided are compositions comprising polymorphic forms of deoxycytidine and at least one residual solvent, as well as methods of treating mitochondrial diseases using said compositions.

Drugs covered by this patent

Kygevvi (DOXECITINE) · Ucb Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4358`	—	Kygevvi

Patent Metadata

Patent number: US11649259
Jurisdiction: US
Classification: Method of Use
Expires: 2040-08-19
Drug substance claim: No
Drug product claim: Yes
Assignee: Zogenix MDS Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.